- The Daily Innovation Newsletter
- Posts
- June 6th 2025
June 6th 2025
The Daily Innovation Newsletter
Enjoying this newsletter? Know someone who would too? Forward this email to them!
June 6th 2025
⏳ 3 days left to read the free sample + join as a Founding Member of Foresight From The Top
Here’s the 10-second version of what you’ll find inside:
🧠 50% of entry-level jobs could vanish within 5 years
💊 Drug discovery now takes weeks, not a decade
🦄 $1B solo-founder startups are already in motion
🤖 Humanoid robots = the new space race
🧬 AGI could arrive before 2030
📚 4 standout articles I read this week
🛠️ A tool I built: Use AI + mental models for CEO-level decisions
👉 Read the full first edition here
🌎 Sustainability
Cornell University researchers have genetically modified Gluconobacter oxydans to extract rare earth elements up to 73% more efficiently and accelerate natural carbon capture by 58 times, offering a sustainable alternative to mining and chemical carbon removal. By enhancing acid production and uncovering new bioleaching pathways, the microbe transforms rocks into long-term CO₂ storage while recovering valuable metals like nickel. The findings, published in Communications Biology and Scientific Reports, could help reduce environmental damage from mining and support critical clean energy supply chains.
Researchers from Purdue University and Sandia National Laboratories have shown that saponite, a naturally abundant clay mineral, can effectively absorb carbon dioxide from the atmosphere, especially in low-humidity conditions. The team discovered that modifying the clay’s ionic structure enhances CO₂ capture, offering a low-cost and scalable alternative to expensive current methods. Published in The Journal of Physical Chemistry C, this breakthrough could transform carbon removal efforts using one of Earth’s most plentiful materials.
Researchers at Worcester Polytechnic Institute, funded by DARPA, are using AI and 3D printing to turn recycled scrap metal into durable rocket components, enabling manufacturing in remote or resource-limited locations. The "Rubble to Rockets" project uses machine learning to predict how mixed alloys will behave, bypassing the need for precise material control in traditional printing methods. A proof-of-concept rocket will demonstrate the approach, which could revolutionize manufacturing for defense, disaster relief, and space missions.
💊 Healthcare
🇺🇸 US startup launches first software to genetically screen IVF embryos for health and longevity traits
Nucleus Genomics has introduced what it claims is the first genetic optimization software for IVF embryos, allowing parents to assess over 900 inherited conditions and traits such as disease risk, height, and cognitive markers. The tool uses polygenic risk scores to help identify embryos with lower chances of developing chronic illnesses, aiming to improve lifelong health outcomes. While medically and ethically controversial, the software reflects a growing push toward personalized, preventive health in reproductive medicine.
Researchers at the Autonomous University of Barcelona have discovered antibiotic-like peptides hidden within human proteins that can effectively kill dangerous, drug-resistant bacteria. One peptide, HBP-5, showed strong activity against gram-negative pathogens and significantly reduced infection in sepsis-infected mice, all with minimal toxicity. Published in Molecular Systems Biology, this breakthrough could lead to a new class of safe, natural antibiotics derived from the body’s own defenses.
Researchers at Indiana University School of Medicine have found that quick digital brain screenings, delivered via iPad during checkups, can detect early signs of Alzheimer’s and dementia, prompting timely diagnosis and care. In one study published in The Annals of Family Medicine, 14% of older patients screened showed potential cognitive issues, with several receiving new diagnoses or early intervention. This technology-driven approach could help integrate brain health into standard care and reduce the burden of late-stage diagnosis.
That’s all for today, please reply to this email if you have any comments or feedback, we’d love to hear from you about what we can do better!
Have you enjoyed this email? Make sure to share it with your friends and colleagues.
See you soon,
Max
Reply